Svennilson Peter 13F annual report

Svennilson Peter is an investment fund managing more than $1.23 billion ran by Peter Svennilson. There are currently 7 companies in Mr. Svennilson’s portfolio. The largest investments include NGM Biopharmaceuticals and Revolution Medicines, together worth $564 million.

$1.23 billion Assets Under Management (AUM)

As of 28th October 2020, Svennilson Peter’s top holding is 18,017,932 shares of NGM Biopharmaceuticals currently worth over $287 million and making up 23.4% of the portfolio value. Relative to the number of outstanding shares of NGM Biopharmaceuticals, Svennilson Peter owns less than 0.3% of the company. In addition, the fund holds 7,977,384 shares of Revolution Medicines worth $278 million, whose value grew 6.5% in the past six months. The third-largest holding is Nurix Therapeutics worth $236 million and the next is RAPT Therapeutics worth $181 million, with 5,630,497 shares owned.

Currently, Svennilson Peter's portfolio is worth at least $1.23 billion. The total portfolio value may be much higher due to cash assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.

Careers at Svennilson Peter

The Svennilson Peter office and employees reside in San Francisco, California. According to the last 13-F report filed with the SEC, Peter Svennilson serves as the Managing Partner of The Column Group GP, LP and affiliates at Svennilson Peter.

Recent trades

In the most recent 13F filing, Svennilson Peter revealed that it had opened a new position in Nurix Therapeutics and bought 6,755,881 shares worth $236 million. This means they effectively own 0.2% of the company. Nurix Therapeutics makes up 21.4% of the fund's Health Care sector allocation and has decreased its share price by approximately 0.1% in the past year.

The investment fund also strengthened its position in NGM Biopharmaceuticals by buying 310,954 additional shares. This makes their stake in NGM Biopharmaceuticals total 18,017,932 shares worth $287 million. NGM Biopharmaceuticals soared 48.5% in the past year.

On the other hand, there are companies that Svennilson Peter is getting rid of from its portfolio. Svennilson Peter closed its position in Arcus Biosciences on 4th November 2020. It sold the previously owned 1,767,676 shares for $43.7 million. Peter Svennilson also disclosed a decreased stake in RAPT Therapeutics by 0.2%. This leaves the value of the investment at $181 million and 5,630,497 shares.

One of the largest hedge funds

The two most similar investment funds to Svennilson Peter are Sirios Capital Management L P and Rheos Capital Works. They manage $1.23 billion and $1.22 billion respectively.

Peter Svennilson investment strategy

Svennilson Peter’s portfolio is diversified across 2 sectors. Currently, their heaviest sector is Health Care — making up 90.0% of the total portfolio value. The fund focuses on investments in the United States as 85.7% of the portfolio companies are based in the United States.

The majority of the companies in the fund’s portfolio are large-cap stocks. Stocks with a size of more than $10 billion in market cap make up approximately 0.1% of the total holdings value. On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio. The average market cap of the portfolio companies is close to $976 million.

The complete list of Svennilson Peter trades based on 13F SEC filings

These positions were updated on November 4th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.

Security	Shares Owned	Value	Allocation
NGM Biopharmaceuticals, Inc.	1.76% 18,017,932	$286,665,000	23.39%
Revolution Medicines, Inc.	No change 7,977,384	$277,613,000	22.65%
Nurix Therapeutics, Inc.	Opened 6,755,881	$235,848,000	19.24%
RAPT Therapeutics, Inc.	16.92% 5,630,497	$181,302,000	14.79%
Constellation Pharmceticls I	No change 6,051,376	$122,601,000	10.00%
Oric Pharmaceuticals, Inc.	No change 4,768,181	$119,252,000	9.73%
Arcus Biosciences, Inc.	Closed 1,767,676	$43,732,000
Gritstone Oncology, Inc.	48.88% 869,493	$2,304,000	0.19%
No transactions found
Showing first 500 out of 8 holdings